Caroline's Feed
Sep 15, 2014

Danaher to buy Nobel Biocare for $2.2 billion

ZURICH (Reuters) – U.S. healthcare group Danaher Corp (DHR.N: Quote, Profile, Research) is to buy Nobel Biocare Holding AG (NOBN.S: Quote, Profile, Research) for an agreed $2.2 billion to become the world’s biggest player in a dental implants market benefiting from growing demand for cosmetic dentistry.

Danaher said on Monday it would pay 17.10 Swiss francs per Nobel Biocare share in cash, about 23 percent above Nobel Biocare’s closing price on July 28, the day before the Swiss firm said it was in talks with potential buyers.

Sep 15, 2014

Danaher to buy Nobel Biocare Holding for $2.2 billion including debt

By Caroline Copley

ZURICH, Sept 15(Reuters) – U.S. healthcare conglomerate Danaher Corp DHR.N is to buy Nobel Biocare Holding AG NOBN.S for an agreed $2.2 billion, including debt, to expand in the global dental industry.

Danaher said on Monday it would pay 17.10 Swiss francs per Nobel Biocare share in cash, about 23 percent above Nobel Biocare’s closing price on July 28, the day before the Swiss firm said it was in talks with potential buyers.

Sep 15, 2014

Danaher to buy Nobel Biocare for $2.2 bln including debt

ZURICH, Sept 15 (Reuters) – U.S. healthcare conglomerate
Danaher Corp is to buy Nobel Biocare Holding AG
for an agreed $2.2 billion, including debt, to expand in the
global dental industry.

Danaher said on Monday it would pay 17.10 Swiss francs per
Nobel Biocare share in cash, about 23 percent above Nobel
Biocare’s closing price on July 28, the day before the Swiss
firm said it was in talks with potential buyers.

Sep 9, 2014

ABB sweetens shareholders with $4 billion buyback as sets out new strategy

LONDON, Sept 9 (Reuters) – Swiss engineering group ABB ABBN.VX said it would buy back $4 billion (2.48 billion pounds) of shares, offering a sweetener to investors after a series of problems at its power systems unit and in the face of sluggish economic growth.

The Zurich-based firm’s Chief Executive Ulrich Spiesshofer is presenting his new strategy and financial targets exactly one year since taking over from predecessor Joe Hogan.

Sep 9, 2014

ABB woos shareholders with $4 billion buyback, trims sales targets

LONDON, Sept 9 (Reuters) – Swiss engineering group ABB ABBN.VX said it would buy back $4 billion of shares, offering a sweetener to investors after a series of problems at its power systems unit and in the face of sluggish economic growth.

The Zurich-based firm’s Chief Executive Ulrich Spiesshofer is presenting his new strategy and financial targets exactly one year since taking over from predecessor Joe Hogan.

Sep 4, 2014

Ex-Genentech boss Levinson resigns from Roche’s board

ZURICH, Sept 4 (Reuters) – Swiss drugmaker Roche
said on Thursday that Art Levinson had resigned from its board
of directors with immediate effect, in order to avoid any
conflict of interest given his role as chief executive at
Google’s Calico.

The move comes a day after Calico partnered with Roche’s
rival AbbVie Inc to invest in new research
operations for age-related diseases.

Sep 3, 2014

Sonova’s microphone disguised as a pen offers “super normal hearing”

ZURICH, Sept 3 (Reuters) – A wireless microphone in the
shape of a pen, made by Switzerland’s Sonova, can help
people with hearing loss understand speech better than those
with normal hearing at certain noise levels, a study has shown.

As the population ages, the hearing aid industry has become
fiercely competitive as manufacturers rush to launch devices
packed with newer technologies that will increase the appeal of
wearing one.

Sep 2, 2014

Swiss growth evaporates in second quarter as trade slows

ZURICH, Sept 2 (Reuters) – Switzerland’s economy
unexpectedly stalled in the second quarter, showing zero growth
as trade took a hit from stagnation in its main export market
Europe and falling construction spending.

The flatlining data, missing forecasts of a 0.5 percent lift
from the previous quarter, was the weakest reported by the State
Secretariat for Economic Affairs in two years and suggested
forecasts for the rest of the year may need to be
cut.

Aug 26, 2014

Straumann passes on Nobel Biocare, eyes China instead

ZURICH, Aug 26 (Reuters) – Straumann, the world’s
largest maker of dental implants, has no interest in joining the
suitors for No.2 player Nobel Biocare, preferring
instead to go after deals in the fast-growing Chinese market, it
said on Tuesday.

The Swiss firm, battling sliding sales in its main market of
Europe, has stepped up its investments in the Asia/Pacific
region, where one in every five dental implants is sold.

Aug 24, 2014

Roche to buy U.S. biotech firm InterMune for $8.3 bln

LONDON/ZURICH, Aug 24 (Reuters) – Roche Holding AG
has agreed to buy U.S. biotech company InterMune Inc
for $8.3 billion in cash, marking the latest multibillion-dollar
deal in a consolidating pharmaceutical sector.

The Swiss drugmaker said on Sunday it would pay $74.00 a
share for InterMune, representing a premium of 38 percent to the
closing price on Aug. 22.